|1.||Goto, Katsuya: 2 articles (09/2012 - 09/2010)|
|2.||Suzuki, Satoshi: 2 articles (09/2012 - 09/2010)|
|3.||Fukushima, Tomoko: 1 article (09/2012)|
|4.||Sato, Michiyoshi: 1 article (09/2012)|
|5.||Ota, Taisei: 1 article (09/2012)|
|6.||Ota, Akiko: 1 article (09/2012)|
|7.||Ota, Shinzo: 1 article (09/2012)|
|8.||Yokoo, Hiroki: 1 article (07/2012)|
|9.||Takebe, Mariko: 1 article (07/2012)|
|10.||Takano, Ken-ichi: 1 article (07/2012)|
03/01/2001 - "In each group, diaphragmatic fatigue was induced by intermittent supramaximal bilateral electrophrenic stimulation at a frequency of 20 Hz applied for 30 min. Immediately after the end of a fatigue-producing period, Group 1 received no study drug, Group 2 was infused with small-dose colforsin daropate (0.2 microg. "
04/01/2003 - "Animals were divided into 3 groups of 8. In each group, diaphragmatic fatigue was induced by intermittent supramaximal bilateral electrophrenic stimulation at a frequency of 20-Hz stimulation applied for 30 min. Immediately after the end of the fatigue-producing period, Group 1 received inhaled vehicle, Group 2 received inhaled colforsin daropate 0.1 mg/mL, and Group 3 received inhaled colforsin daropate 0.2 mg/mL. We assessed diaphragmatic contractility by transdiaphragmatic pressure (Pdi). "
03/01/2001 - "Colforsin daropate improves contractile properties during diaphragmatic fatigue."
|3.||Pulmonary Hypertension (Ayerza Syndrome)
03/01/2002 - "Colforsin daropate may attenuate bronchoconstriction and pulmonary hypertension. "
03/01/2002 - "To determine whether colforsin daropate-induced relaxation is independent of plasma catecholamine, propranolol 0.4 mg/kg was given following colforsin daropate 300 microg/kg i.v. Colforsin daropate reversed both pulmonary hypertension and bronchoconstriction dose-dependently: -logED50 (95% confidence intervals, mean ED50) for pulmonary hypertension and bronchoconstriction 5.44 (5.08-5.80, 3.6 microg/kg) and 4.90 (4.06-5.20, 12.5 microg/kg), respectively. "
03/01/2002 - "Spasmolytic effects of colforsin daropate on serotonin-induced pulmonary hypertension and bronchoconstriction in dogs."
03/01/2002 - "In the present study we have simultaneously evaluated the spasmolytic effects of colforsin daropate, a novel forskolin derivative, on serotonin-induced pulmonary hypertension and bronchoconstriction. "
12/01/2002 - "These results suggest that colforsin daropate may be preferable in the treatment of severe heart failure where the coronary blood flow is reduced and beta-adrenoceptor-dependent signal transduction pathway is down-regulated."
11/01/2001 - "Colforsin daropate hydrochloride (COL) is a novel drug for the treatment of acute heart failure. "
11/01/2001 - "[Cardiovascular effects of colforsin daropate hydrochloride for acute heart failure after open heart surgery]."
08/01/1999 - "[Cardiovascular effects of colforsin daropate hydrochloride, a novel drug for the treatment of acute heart failure]."
08/01/2007 - "A novel water-soluble forskolin derivative, colforsin daropate hydrochloride (CDH) is a positive inotropic agent for treatment of the heart failure, especially in the severe stage with the beta1 AR desensitization. "
09/01/2012 - "Colforsin daropate hydrochloride (CDH) has also recently been reported to be useful for reversal of cerebral vasospasm (CV). "
01/01/2006 - "We suggest that colforsin daropate HCl might be a useful therapeutic tool in treating cerebral vasospasm."
09/01/2010 - "Intra-arterial colforsin daropate for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage."
|2.||Adenylate Cyclase (Adenylyl Cyclase)
|3.||Serotonin (5 Hydroxytryptamine)